siRNA Therapy Successfully Switches Off Harmful Genes: FDA-Approved Patisiran and Other Drugs for Hereditary Amyloidosis

Works in Progress Magazine UK

Overview

siRNA therapy is emerging as a promising treatment to slow or halt disease progression by temporarily silencing specific genes. For conditions like hereditary transthyretin amyloidosis, FDA-approved drugs such as patisiran and vutrisiran use siRNA to prevent mutant protein production and treat nerve damage. While gene silencing in the liver is a solved problem, offering treatments for hypercholesterolemia and acute hepatic porphyria with only a few doses annually, effective targeted delivery to other tissues and minimizing off-target effects remain key challenges.

In Depth

Key Findings

siRNA (small interfering RNA) therapy is rapidly establishing itself as a revolutionary treatment modality with the potential to slow or even halt the progression of diseases by temporarily switching off specific gene expressions. This innovative ‘kill switch’ technology offers new hope for a range of previously untreatable genetic disorders.

Technical & Clinical Details

• Gene Silencing Mechanism: siRNA molecules bind to specific messenger RNA (mRNA) sequences, leading to their degradation and, consequently, the suppression of corresponding protein production. This effectively halts the synthesis of harmful proteins responsible for disease pathogenesis, leveraging the cell’s natural RNA interference (RNAi) defense mechanism.
• Approved Therapies and Efficacy:
  • Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis): FDA-approved siRNA drugs like patisiran (Onpattro) and vutrisiran (Amvuttra) have been introduced for this rare, progressive neurodegenerative disease. These drugs effectively treat nerve damage and significantly improve patient quality of life by inhibiting the production of mutant transthyretin protein.
  • Hypercholesterolemia: Inclisiran (Leqvio), an siRNA targeting PCSK9 protein production, dramatically reduces low-density lipoprotein (LDL) cholesterol levels with only a few subcutaneous injections per year, offering a breakthrough for patients at high cardiovascular risk.
  • Acute Hepatic Porphyria (AHP): Givosiran (Givlaari), an siRNA drug that suppresses ALAS1 enzyme production—the cause of AHP—reduces severe attacks and enhances patient quality of life.
• Liver-Targeted Success and Challenges: siRNA therapy has achieved significant success with efficient delivery to the liver, making it a promising approach for many liver-related disorders. However, effective drug delivery to extrahepatic target tissues (e.g., brain, muscle) and minimizing unintended off-target effects remain major challenges in ongoing technological development.

Background & Context

siRNA therapy stands apart from conventional symptomatic treatments or protein replacement therapies by addressing the root cause of diseases at the genetic level. Originating from the discovery of ‘co-suppression’ in plants in the 1990s, the concept of RNA interference was later demonstrated in mammals, leading to serious pharmaceutical development in the 21st century. This technology, capable of ‘programmably switching off’ specific genes, is considered a pinnacle of personalized medicine. The pharmaceutical industry is heavily invested in advancing siRNA technology due to its broad therapeutic potential.Strategic Significance & Outlook

Future siRNA research will primarily focus on further innovations in delivery technologies. Enhancements in lipid nanoparticle (LNP) and GalNAc conjugate technologies for efficient and safe siRNA delivery to specific cells and tissues will be crucial. Rigorous assessment and minimization of off-target effects, along with establishing long-term safety profiles, are also imperative. siRNA therapy holds the potential to accelerate the realization of ‘programmable medicine’ across a wide spectrum of diseases, from rare conditions to common chronic ailments like hypertension and diabetes, thereby profoundly transforming the future of healthcare.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime